Related to Flush with Cash, Versartis and Diartis Focus on Drugs Based on Amunix’ XTEN Technology

• BioMimetic Strengthens Arrangement with Novartis for Exclusive Supply of Recombinant Human Platelet-Derived Growth Factor
  
• Adocia Raises Over $20M to Take BioChaperone Growth-Factor Treatments into Phase I Trials
  
• Researchers Identify Gene Variants Influencing Insulin/Glucose Regulation
  
• Japan Sanctions Three Novartis Drugs for Hypertension, Advanced Renal Cancer, and Type 2 Diabetes
  
• Novo Nordisk Gains Approval for Type 2 Diabetes Treatment in Japan
  
• Intrinsic Licenses Two Type 2 Diabetes Markers to Ortho-Clinical Diagnostics
  
• Researchers Find Mechanism for Cellular Dysfunction and Apoptosis in Type 2 Diabetes
  
• Lilly Negotiates Option to License Alizé’s Preclinical Type 2 Diabetes Program
  
• Novo Nordisk’s Type 2 Diabetes Drug Green-Lighted by FDA
  
• Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy
  
• FDA Stalls Approval of Amylin, Lilly, and Alkermes’ Type 2 Diabetes Therapy
  
• Catabasis Pockets $39.6M in a Series A Funding
  
• Zealand Pharma and Sanofi-Aventis Expand Type 2 Diabetes-Focused Partnership
  
• Ortho-McNeil-Janssen Inks Two Diabetes-Focused Deals Together Worth over $1B
  
• Sanofi-Aventis to Develop Metabolex’ Type 2 Diabetes Therapy as Part of $375M Deal
  
• Published Studies Uphold Health Risk Concerns about GSK’s Type 2 Diabetes Drug
  
• Reata Scores $78M to Test CKD Candidate in Second Phase III Trial
  
• Tethys Secures $33M to Aid Marketing of Type 2 Diabetes Test
  
• GSK Halts Enrollment for Postmarketing Avandia Trial as FDA Reviews Safety
  
• Janssen Licenses Drug-Delivery Technology from Depomed